Longport signs $5 million R&D deal
Ultrasound developer Longport of Swarthmore, PA, last month signed an agreement with Healthlink International of Westerville, OH, in which Healthlink will invest $5 million to support Longport’s R&D efforts. The funds will be used to expand the
Ultrasound developer Longport of Swarthmore, PA, last month signed an agreement with Healthlink International of Westerville, OH, in which Healthlink will invest $5 million to support Longports R&D efforts. The funds will be used to expand the companys list of applications for its Longport Digital Scanner (LDS), a portable ultrasound scanner that captures and reproduces images of soft tissue down to 2 cm (SCAN 1/13/99). Healthlink has also purchased an equity interest in Longport, according to the company.
Longport applied for 510(k) clearance for LDS in January, and hopes to receive clearance this month. The companys application to the Food and Drug Administration covers the use of LDS for dermatological indications, but Longport plans to research other indications, including podiatric, physical therapy, dental, burn treatment, and such oncologic applications as breast and cervical cancer.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
